GlassScriptPhysician profile
Kate S Wheeler
NPI 1639121056
$16,974.31
in general payments reported to CMS, 2019-2025
65 companies · $2,857 in 2025
The $2,857 reported for 2025 was more than what 82% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,219 · 2020: $827 · 2021: $1,315 · 2022: $2,894 · 2023: $3,053 · 2024: $2,809 · 2025: $2,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,440 · Education: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,439.57 |
| Education | $280.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,881.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,384.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $1,145.11 | 2019-2025 | Korlym |
| Mannkind Corporation | $1,132.16 | 2019-2025 | Afrezza |
| Amgen INC. | $1,111.07 | 2019-2025 | Tepezza, Evenity, Prolia |
| Tandem Diabetes Care, INC. | $1,071.54 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $894.56 | 2019-2025 | |
| Abbott Laboratories | $768.05 | 2019-2025 | Freestyle Libre 3 |
| Insulet Corporation | $752.70 | 2019-2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $608.90 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Radius Health, INC. | $574.53 | 2019-2025 | Tymlos |
| Beta Bionics, INC. | $545.63 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bigfoot Biomedical INC | $427.39 | 2022-2023 | Unity Diabetes Management System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.86 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Ibsa Pharma INC. | $325.33 | 2019-2025 | Tirosint, Flector, Licart |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kate Wheeler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.